TxCell develops innovative, personalized cellular immunotherapies using regulatory T cells (Treg) to treat severe chronic inflammatory and autoimmune diseases. TxCell is developing two proprietary technology platforms, ASTrIA and ENTrIA.

ASTrIA is composed of autologous antigen specific Type 1 Regulatory T cells (Ag-Treg). It uses the natural immuno-modulatory properties of Ag-Treg cells. Patient's purified blood cells are educated ex-vivo to recognize a chosen antigen.

ENTrIA is composed of Chimeric Antigen Receptor (CAR) engineered FoxP3+ Regulatory T cells (CAR-Treg). After their isolation from the blood of patients, FoxP3+ Treg cells are genetically modified by transduction with a CAR.

TxCell's lead drug-candidate Ovasave® originates from the ASTrIA platform. A phase IIb placebo-controlled study has been initiated in refractory Crohn's Disease patients. This follows a phase I/IIa study in the same patient population, which has been successfully completed and reported positive clinical efficacy and good tolerability (link1 & link2).



2015 Registration Document (Document de Référence) - 24/05/2016    Corporate Presentation - June 2016 - 23/06/2016
 DDR 2014             Corporate Presentation

Arnaud Foussat, "Multiple ways to genetically alter T cells", MedNous, Vol 10, N° 7, July-August 2016, 6-7.

MedNous July-August 2016 issue - Arnaud Foussat commentary        




August 21-26, 2016
International Congress of Immunology 2016 (ICI 2016), Melbourne, Australia


September 21-22, 2016
Phacilitate Leaders Forum (including both Cell & Gene Therapy Europe and Immunotherapy Europe), Berlin, Germany


September 30 - October 2, 2016
International Society for Cellular Therapy (ISCT) North America 2016 Regional Meeting, Memphis, United States